Updated UK Recommendations for HER2 assessment in breast cancer

The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation

(2014) Andrew H S Lee et al.   JOURNAL OF CLINICAL PATHOLOGY

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

(2013) Frédérique Penault-Llorca et al.   BREAST

Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: Experience from a tertiary care centre in India

(2013) Prashant Durgapal et al.   DIAGNOSTIC CYTOPATHOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

(2013) Wedad M Hanna et al.   MODERN PATHOLOGY

Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis

(2012) Xiaosong Chen et al.   BREAST CANCER RESEARCH AND TREATMENT

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast

(2012) Andrew H S Lee et al.   HISTOPATHOLOGY

Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?

(2012) Lauren T. Greer et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)

(2012) Laurent Arnould et al.   MODERN PATHOLOGY

HeterogeneousHER2Gene Amplification

(2011) Alastair I. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

HER2 genetic heterogeneity in breast carcinoma

(2011) C. Ohlschlegel et al.   JOURNAL OF CLINICAL PATHOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

(2010) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

(2009) M. Arnedos et al.   ANNALS OF ONCOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

HER-2/neu analysis in breast cancer bone metastases

(2009) J Zustin et al.   JOURNAL OF CLINICAL PATHOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 testing in the UK: further update to recommendations

(2008) R A Walker et al.   JOURNAL OF CLINICAL PATHOLOGY